



(43) International Publication Date
02 February 2023 (02.02.2023)


- (51) International Patent Classification:
A61M 1/36 (2006.01) A61B 5/026 (2006.01)
- (21) International Application Number:
PCT/US2022/038495
- (22) International Filing Date:
27 July 2022 (27.07.2022)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
17/387,391 28 July 2021 (28.07.2021) US
- (71) Applicant: **TRANSONIC SYSTEMS INC.** [US/US]; 34 Dutch Mill Road, Ithaca, New York 14850 (US).
- (72) Inventors: **KRIVITSKI, Nikolai M.**; 227 Highgate Road, Ithaca, New York 14850 (US). **GALYANOV, Gregory**; 199 Christopher Lane, Ithaca, New York 14850 (US).

(74) Agent: **SHAW, Brian B.** et al.; 1600 Bausch and Lomb Place, Rochester, New York 14604 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: METHOD AND APPARATUS FOR IDENTIFYING DISRUPTION OF A FLUID CONNECTION BETWEEN AN EXTRACORPOREAL CIRCUIT AND A PATIENT CIRCULATORY SYSTEM



(57) Abstract: A system and method for identifying a disruption of a flow from an extracorporeal circuit to a patient circulatory system is based on flow rate data, such as from a venous line of the extracorporeal circuit. A patient contribution to the flow rate data is identified and monitored to assess a disruption of the extracorporeal circuit and the patient circulatory system, or access device. A spectrum analysis can be performed on the flow rate data to identify a harmonic corresponding to the patient contribution, wherein a change in or disappearance of the identified harmonic can be used to identify a disruption of the flow.



WO 2023/009606 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

METHOD AND APPARATUS FOR IDENTIFYING DISRUPTION OF A FLUID CONNECTION BETWEEN AN EXTRACORPOREAL CIRCUIT AND A PATIENT CIRCULATORY SYSTEM

CROSS-REFERENCE TO RELATED APPLICATIONS

[1] Not applicable.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[2] Not applicable.

THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT

[3] Not applicable.

REFERENCE TO A SEQUENCE LISTING

[4] Not applicable.

STATEMENT REGARDING PRIOR DISCLOSURES BY THE INVENTOR OR A JOINT INVENTOR

[5] Not applicable.

BACKGROUND OF THE INVENTION

Field of the Invention

[6] The present disclosure relates to an apparatus and a method for detecting a disruption of a fluid connection between an extracorporeal circuit and a patient circulatory system, and particularly to an apparatus and method for detecting a disruption downstream of a blood pump in a blood treatment apparatus in an extracorporeal circuit, including but not limited to a venous needle dislodgement (VND), and more particularly to an apparatus and method for identifying a disconnect of a venous line of an extracorporeal circuit and a patient circulatory system, wherein the disconnect corresponds to a change in a patient contribution to flow rate data in the extracorporeal circuit, and particularly the venous line.

Description of Related Art

[7] A variety of different medical treatments relate to the delivery of fluid to, through and/or from a patient, such as the delivery of blood between a patient and an extracorporeal system connected to the patient via a needle, or needles, or catheters inserted into the patient. For example, hemodialysis, hemofiltration and hemodiafiltration are all treatments that remove waste, toxins and excess water from the blood. During these treatments, the patient is connected to an extracorporeal circuit and machine, and the blood is pumped through the circuit and the machine. Waste, toxins and fluid are removed from the blood, and the cleaned blood is returned to the patient.

[8] In these treatments, needles or catheters or similar access devices are inserted into the vascular system of the patient so that the blood can be transported to and from the extracorporeal machine. Traditional hemodialysis, hemofiltration and hemodiafiltration treatments can last several hours or days or even weeks and are generally performed in a treatment center. For in-center treatments, patients undergoing hemodialysis, for example, are monitored visually to detect needle dislodgment. However, the needle may not be in plain view of the patient or medical staff (e.g., it may be covered by a blanket) such that it could delay detection of any disruption and an appropriate timely response.

[9] Moreover, in view of the increased quality of life, observed reductions in both morbidity and mortality and lower costs with respect to in-center treatments, a renewed interest has arisen for self-care and home therapies, such as home hemodialysis. Such home therapies (whether hemodialysis, hemofiltration or hemodiafiltration) can be performed during the day, evening or nocturnally. If unsupervised or asleep, dislodgment risks increase because a caregiver is not present and perhaps even the patient is not aware of a dislodgment.

[10] However, dialysis is a complicated procedure that is historically carried out by a team of trained professionals who are responsible for delivering safe and effective care to the patient. Recently, the dialysis can also be self-administered by a patient in their home. However, there are still many ways that complications can arise during a dialysis session. While many of these potential issues are constrained by alarm circuits and other safeguards built into the dialysis

machine, needle dislodgement (including displacement) can sometimes remain undetected or only detected after a significant time delay.

[11] In extracorporeal blood processing, it is important to minimize the risk for malfunctions in the extracorporeal circuit, since these may lead to a potentially life-threatening condition of the patient. Serious conditions may arise if the extracorporeal circuit is disrupted downstream of the blood pump, e.g. by a venous needle dislodgement (VND) event, in which the venous needle comes loose from the patient or from the patient access. Such a disruption may cause the patient to be drained of blood within minutes.

[12] Specifically, the connection of the extracorporeal circuit to the venous access may become disturbed, if, for example, the needle or cannula gets out of place and the extracorporeal circulation is no longer connected properly, or is no longer connected at all, to the patient. This may cause problems especially in the case of dislodgement of the venous access to the vascular system of the patient. Unless such dislodgement of the venous access is detected in due time, blood continues being withdrawn from the patient via the arterial access but is no longer properly returned into the patient after the extracorporeal blood treatment. In the case of common blood flow rates of 300 to 400 ml/min, for example, a critical situation will develop within a few minutes.

[13] Conventionally, VND may be detected during blood processing based on a pressure signal from a pressure sensor (“venous pressure sensor”) on the downstream side of the blood pump in the extracorporeal circuit. However, it may be difficult to set appropriate threshold values, since the pressure in the extracorporeal circuit may vary between treatments, and also during a treatment, such as for example as a result of the subject moving. Further, if the extracorporeal circuit comes loose and gets stuck in bed sheets or the subject's clothes, the measured pressure level might not change enough to indicate the potentially dangerous situation.

[14] Therefore, the need exists for improved systems and methods for detecting a disruption of a fluid connection between an extracorporeal circuit and a patient circulatory system and particularly for detecting a disruption downstream of a blood pump in a blood treatment apparatus in an extracorporeal circuit, including but not limited to a venous needle dislodgement (VND) or connection to the catheter dislodgement.

BRIEF SUMMARY OF THE INVENTION

[15] Generally, the present disclosure provides an apparatus for monitoring an extracorporeal circuit extending from a patient blood withdrawal site through an extracorporeal blood treatment device and back to a patient blood delivery site, wherein the extracorporeal circuit comprises a blood withdrawal line extending from the patient blood withdrawal site to the blood treatment device, a blood delivery line extending from the blood treatment device to the patient blood delivery site, and a pump operable to pump blood through the extracorporeal circuit from the blood withdrawal line, through the blood treatment device and through the blood delivery line to the patient blood delivery site, the apparatus including a flow sensor configured to obtain flow rate data of a blood flow in at least one of the blood withdrawal line and the blood delivery line; and a controller in communication with the flow sensor, wherein the controller is configured to identify, in the flow rate data, a patient contribution to the flow rate data from a patient physiological process; and detect, based at least partly on the identified patient contribution, a disruption of the extracorporeal blood path.

[16] In one configuration, the present disclosure provides a monitor for monitoring an extracorporeal blood path extending from a vascular access through an extracorporeal blood treatment device and back to the vascular access, wherein the extracorporeal blood path comprises an arterial line as a blood withdrawal line extending from a vascular access to the blood treatment device, a venous line as a blood delivery line extending from the blood treatment device to the vascular access, and a pump operable to pump blood through the extracorporeal blood path from the arterial line, through the blood treatment device and through the venous line to the vascular access, the monitor including a flow sensor for obtaining flow rate data of a blood flow in the venous line; and a controller in communication with the flow sensor, the controller configured to (i) identify, in the obtained flow rate data, a patient contribution to the flow rate data from a downstream patient physiological process; and (ii) detect, based at least partly on the identified patient contribution, a disruption of flow between the extracorporeal blood path and the patient. It is further disclosed that the controller can (i) determine, based on the obtained flow rate data, a flow rate in the venous line; (ii) identify, in the determined flow rate, a patient contribution to the flow rate from a downstream patient physiological process; and (iii) detect,

based at least partly on the identified patient contribution, the disruption of flow between the extracorporeal blood path and the patient.

[17] The present disclosure also contemplates the disruption can be identified from obtaining flow rate data from the arterial (blood withdrawal) line as well as or in place of flow rate data from the venous (blood delivery) line. In addition, the disruption can be identified by comparing or correlating the flow rate data from the venous line and the arterial line, as well as changes in such comparison or correlation of the flow rate data.

[18] The present disclosure further contemplates a controller connected to a flow sensor sensing flow rate data through a venous (blood delivery) line of an extracorporeal circuit, the controller configured to identify a disruption in a blood flow path downstream of the flow sensor corresponding to a change in, or disappearance of, a patient contribution to flow rate data in the venous line.

[19] A method is disclosed including identifying a disruption of a connection of a venous (blood delivery) line of an extracorporeal circuit and a patient circulatory system, wherein the disruption corresponds to a change in, or disappearance of, a patient contribution to flow rate data in the venous line.

[20] A further method includes identifying a patient contribution from a downstream patient physiological function of measured flow rate data in a venous (blood delivery) line of an extracorporeal circuit; and monitoring the patient contribution to identify a disruption of a vascular access.

[21] An additional method is provided of measuring flow rate data in a venous (blood delivery) line of an extracorporeal circuit having a pump imparting a flow in the venous line; and identifying a disruption of the venous line and a circulatory system corresponding to a change of a component of the measured flow rate data, which component corresponds to a physiological parameter of a downstream circulatory system connected to the venous line.

[22] The present disclosure also includes a method for monitoring an extracorporeal blood treatment apparatus that comprises an extracorporeal blood circuit, the extracorporeal blood circuit having an arterial blood line with an arterial patient connection and a venous blood line

with a venous patient connection, and a pump for conveying blood in the extracorporeal blood circuit, the method including measuring blood flow rate data in the venous blood line of the extracorporeal blood circuit; identifying a patient contribution of the measured blood flow rate data corresponding to a downstream physiological parameter of the patient; determining a presence of a disruption of flow between the extracorporeal circuit and the patient circulatory system in response to a change in, or disappearance of, the patient contribution to the measured blood flow rate data; and generating a control signal to activate an alarm unit, stop the pump, or both, after the step of determining the presence of the disruption.

[23] The following will describe embodiments of the present disclosure, but it should be appreciated that the present disclosure is not limited to the described embodiments and various modifications of the invention are possible without departing from the basic principles. The scope of the present disclosure is therefore to be determined solely by the appended claims.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

[24] Fig. 1 is a schematic of a representative extracorporeal circuit.

[25] Fig. 2 is a graph of flow rate versus time in a venous line in the extracorporeal circuit.

[26] Fig. 3 is a graph of flow rate versus time in an arterial line in the extracorporeal circuit.

[27] Fig. 4 is a graph of frequencies from a spectrum analysis of the measured flow rate in the venous line of the extracorporeal circuit.

[28] Fig. 5 is a graph of frequencies from a spectrum analysis of the measured flow rate in the arterial line of the extracorporeal circuit.

[29] Fig. 6 is a graph of frequencies from a spectrum analysis of the measured flow rate in the arterial line and the venous line of the extracorporeal circuit.

[30] Fig. 7 is a second graph of flow rate versus time in a venous line in the extracorporeal circuit.

[31] Fig. 8 is a second graph of flow rate versus time in an arterial line in the extracorporeal circuit.

[32] Fig. 9 is graph of frequencies from a spectrum analysis (FFT) of the measured flow rate in the venous line of the extracorporeal circuit of Fig. 7 showing harmonics from the physiology of the patient.

[33] Fig. 10 is graph of frequencies from a spectrum analysis (FFT) of the measured flow rate in the arterial line of the extracorporeal circuit of Fig. 8.

DETAILED DESCRIPTION OF THE INVENTION

[34] Referring to Fig. 1, an extracorporeal circuit (“EC circuit”) 100 is shown connected to a circulatory system of a patient.

[35] The extracorporeal circuit 100 extends from a patient blood withdrawal site 110 through a blood treatment device 130 and back to a patient blood delivery site 160, wherein the extracorporeal circuit comprises a blood withdrawal line 120 extending from the patient blood withdrawal site to the blood treatment device, a blood delivery line 150 extending from the blood treatment device to the patient blood delivery site, and a pump 170 configured to pump blood through the extracorporeal circuit from the blood withdrawal line, through the blood treatment device and through the blood delivery line to the patient blood delivery site. A flow sensor is configured to obtain blood flow rate data from at least one of the blood withdrawal line 120 and the blood delivery line 150. In certain configurations, a flow sensor 126 obtains flow rate data from the blood withdrawal line 120 and a flow sensor 156 obtains flow rate data from the blood delivery line 150. A controller 180 is connected to at least one of the flow sensors 126, 156, and the pump 170.

[36] In one configuration, the extracorporeal circuit 100 is configured to provide dialysis wherein the blood withdrawal line 120 is referred to as an arterial line, the blood treatment device 130 includes, but not limited to a dialyzer, and the blood delivery line 150 is referred to as a venous line. For purposes of description, the blood travels from an access device 200 to the arterial line 120 and returns to the access device in the venous line 150. Although, the extracorporeal circuit 100 is shown with both the arterial sensor 126 and the venous flow sensor

156, it is understood that the disclosed system may be practiced without or with the use of the arterial flow sensor.

[37] For purposes of description in terms of dialysis nomenclature, the blood travels from the patient blood withdrawal site 110 to the arterial line 120 (the blood withdrawal line) and returns to the patient blood delivery site 160 through the venous line 150 (the blood delivery line). In this nomenclature, the flow sensor 126 obtaining flow rate data in the arterial line is referred to as the arterial flow sensor 126 and the flow sensor 156 obtaining flow rate data in the venous line is referred to as the venous flow sensor 156.

[38] While the system is shown with both the arterial flow sensor 126 and the venous flow sensor 156, it is understood that the present disclosure can be practiced with just the arterial flow sensor 126, just the venous flow sensor 156, or both the arterial flow sensor and the venous flow sensor.

[39] As set forth above, in one configuration, the extracorporeal circuit 100 is configured to provide extracorporeal blood treatment. In extracorporeal blood treatment, blood is taken out of a patient, processed (e.g. treated) and then reintroduced into the patient by means of the extracorporeal circuit 100 which can be part of the blood treatment device 130.

[40] Extracorporeal blood treatment includes hemodialysis, hemodiafiltration, hemofiltration, plasmapheresis, etc., including the clearance of toxins from the blood, such as by diffusion across a membrane.

[41] For purposes of the present description, the following terminology is used. The term “flow rate data” is any data from which a flow rate can be derived, assessed, or calculated, as well as any surrogate data for deriving, assessing, or calculating the flow rate. It is further contemplated that the flow rate can be the actual blood flow rate, the calculated blood flow rate, or a predicted flow rate, as well as any surrogate of the actual blood flow rate, such as but not limited to a flow velocity, or a value proportional or related to the blood flow or the velocity. The flow rate data encompasses any signals or data related to the blood flow, and particularly related to any pulsatile, varying, frequency dependent, or oscillatory component or characteristic of the flow, such as indicated by any signals, such as but not limited to optical signals, acoustic

signals, electromagnetic signals, temperature signals and other signal that can be source of frequency analysis. Thus, the flow rate data includes any signals or data representing the flow rate or signals or data from which the flow rate, or any pulsation, variation, frequency variation, or oscillation of the flow rate, or pulsation, variation, frequency variation, or oscillation in the flow rate can be determined, or sensed, or any corresponding surrogates. For example, markers in the blood, including native or introduced particles could be used as the surrogate. Thus, the term flow rate is intended to encompass any value or measurement that corresponds to, is a surrogate of, or can represent the blood flow and especially to any pulsation, variation, frequency variation, oscillation, or a characteristic or property of the blood flow. The term “flow rate” (or “blood flow rate”) thus encompasses the volumetric flow rate as a measure of a volume of liquid passing a cross-sectional area of a conduit per unit time, and may be expressed in units of volume per unit time, typically milliliters per min (ml/min) or liters per minute (l/min), and any of its surrogates. It is understood the blood flow rate can be measured as well as calculated by any of a variety of known systems and methods.

[42] The access device 200 fluidly connects to a circulatory system such as a human (or animal) circulatory system which includes blood, a vascular system having a cardiopulmonary system and a systemic system connecting the cardiopulmonary system to the tissues of the body, and a heart. Specifically, the systemic system passes the blood through the vascular system (arteries, veins, and capillaries) throughout a patient body. Thus, the access device 200 fluidly connects to the circulatory system and provides access to the extracorporeal circuit 100. The term “access device” encompasses any access to the circulatory system of the patient and includes but not limited to catheters, needles, shunts, AV native fistulae, AV-artificial graft; as well as a venous catheter, or other vascular implantations. The connection of the extracorporeal circuit 100 to the patient, via the access device 200, usually includes catheters or cannulas or needles, e.g. dialysis cannulas, where the access device 200, for example, is punctured and fluid communication is established. As set forth herein, the access device 200 encompasses the patient blood withdrawal site 110 as well as the patient blood delivery site 160. Thus, the access device 200 includes separate arterial access and venous access as well as arterial access and venous access that are proximal or adjacent, or within a common shunt, line, or graft.

[43] The term “blood treatment” means any blood processing including but not limited to dialysis, which in turn includes toxin clearance such as by diffusive therapy including but not limited to hemofiltration, hemodialysis, hemodiafiltration, or Continuous Renal Replacement Therapy (CRRT). A blood treatment device is any device for imparting the blood treatment. Thus, in one configuration, the blood treatment device, such as the dialyzer, can be configured to provide controllable transfer of solutes and water across a semi permeable membrane separating flowing blood and dialysate streams. Such a transfer process may include diffusion (dialysis) and convection (ultra-filtration). The blood treatment device may provide any of a host of other blood treatments, such as chemical treatment, electromagnetic treatment as well as thermal treatment.

[44] The term blood includes treated or untreated blood, including artificial or natural blood, as well as plasma.

[45] The term “disruption” encompasses any diversion, disconnection, dislodgement, or interruption of the flow in the extracorporeal circuit 100 and in certain configurations an interruption downstream of the pump 170, and in certain configurations downstream of the blood treatment device 130, as well as from the extracorporeal circuit 100 to the access device 200 or from the access device to the circulatory system, including the patient blood withdrawal site 110 as well as the patient blood delivery site 160, such as a venous needle dislodgement, or disconnect.

[46] The term “controller” includes signal processors and computers, including programmed desk or laptop computers, or dedicated computers for processors. Such controllers can be readily programmed to perform the recited calculations, or derivations thereof, to provide determinations of the flow rate and transforms of the flow rate data as set forth herein. The controller can also perform preliminary signal conditioning such as summing one signal with another signal or portion of another signal.

[47] The term “flow sensor” encompasses any sensing device that provides a signal representing the flow rate data or data from which the flow rate, any pulsation, variation, frequency change, or oscillation in the flow rate, or surrogate of the flow rate, pulsation, variation, frequency change, or oscillation in the flow rate can be determined, or sensed.

[48] The term "upstream" of a given position refers to a direction against the flow of blood, and the term "downstream" of a given position is the direction of blood flow away from the given position. The "arterial line" or side is that part of the extracorporeal circuit 100 which blood passes from the patient blood withdrawal site 110, such as the access device 200 to flow to the blood treatment device 130. The "venous line" or side is that part of the extracorporeal circuit 100 which blood passes from the blood treatment device 130 to the patient blood delivery site 160, such as the access device 200.

[49] Generally, the blood is circulated through the extracorporeal circuit 100 by the pump 170. It is understood, the present disclosure encompasses the extracorporeal circuit 100, wherein the blood treatment device 130 (such as an extracorporeal membrane oxygenator, ECMO) withdraws blood from the venous portion of the patient circulatory system, and returns treated (oxygenated) blood to a second venous portion of the patient circulatory system as well as configurations wherein the blood is removed from either the venous portion or the arterial portion of the patient circulatory system and is returned to either the venous portion or the arterial portion of the patient circulatory system, wherein the detected disruption can be in any of these configurations.

[50] It is also contemplated that the present disclosure encompasses the extracorporeal circuit 100 having a plurality of patient blood withdrawal sites 110, a plurality of blood withdrawal lines 120, a plurality of blood treatment devices 130, a plurality of pumps 170, a plurality of blood delivery lines 150 and a plurality of patient blood delivery sites 160, or any combination thereof. Thus, the present system can have more than one blood delivery line 150 to the patient. It is understood that in certain types of extracorporeal blood treatment, the extracorporeal circuit 100 includes the arterial needle for blood withdrawal and the venous needle for blood reintroduction, wherein the needles are inserted into the access device 200. Thus, in select configurations, the extracorporeal circuit 100 withdraws blood from the access device 200 and returns the blood to the access device. The withdrawn blood can be treated while it is withdrawn, such as through the dialyzer 130 before being returned through the venous line 150 to the access device 200.

[51] In one configuration, the blood passes from the access device 200, through the pump 170, then through the blood treatment device 130, such as the dialyzer. The blood then passes from the blood treatment device 130 to the access device 200. Although not shown, it is contemplated

the venous line 150 can include an air trap and air detector between the blood treatment device 130 and the access device 200.

[52] Depending upon the configuration of the extracorporeal circuit 100 and the mechanisms for measuring the blood parameters, the arterial line 120 can also include or provide an introduction port as a site for introducing a material into the extracorporeal circuit 100.

[53] The venous line 150 connects the flow of the extracorporeal circuit 100 to the circulatory system, such as through the access device 200. The venous line 150 typically includes a return (venous) cannula providing the fluid connection to the access device 200.

[54] The venous line 150 includes the flow sensor 156. The flow sensor 156 measures a flow characteristic or parameter to generate flow rate data, from which the flow rate, or any flow pulsation, variation, frequency change, or oscillation component, or flow frequency components can be determined. Thus, the flow sensor 156 can include a flow rate sensor, an ultrasound sensor or even a dilution sensor for sensing passage of the indicator through the extracorporeal circuit 100. The flow sensor 156 can be any of a variety of sensors which obtain flow rate data. In select configurations, the flow sensor 156 (as well as sensor 126) can measure different blood properties: such as but not limited to temperature, Doppler frequency, electrical impedance, optical properties, density, ultrasound velocity, concentration of glucose, oxygen saturation and other blood substances (any physical, electrical or chemical blood properties). Alternatively, there can be an additional sensor (not shown) in addition to flow sensor 156 to measure select blood characteristics or properties.

[55] The flow sensor 126 in the arterial line 120 can be any of a variety of sensors, as set forth in the description of the sensor 156. While the system is described with the two sensors 126, 156, for an enhanced accuracy, it is understood only a single flow sensor is necessary. It is further contemplated that any imparted flow pulsation from the pump 170 can be identified such as through an operating parameter of the pump, including the revolutions per minute of operation of the pump, wherein this contribution is distinguished from any patient contribution

[56] Specifically, in the arterial line 120, the flow sensor 126, if employed, can be any of a variety of sensors to obtain the flow rate data. The sensor 126 can measure different blood

properties: such as but not limited to temperature, Doppler frequency, electrical impedance, optical properties, density, ultrasound velocity, concentration of glucose, oxygen saturation and other blood substances (any physical, electrical or chemical blood properties) that are related to, correspond to or evidence the blood flow rate and pulsation, oscillation, variation or frequency change within, or time variation of the flow rate. It is also understood the flow sensor 126 can also measure the blood flow rate. Thus, in one configuration the present system includes a single blood property sensor and a single flow rate sensor. It is further contemplated that a single combined sensor for measuring flow rate and a blood parameter (property) can be used.

[57] It is also understood the sensors 126, 156 can be located outside of the extracorporeal circuit 100. That is, the sensors 126, 156 can be remotely located and measure in the extracorporeal circuit 100, the changes produced in the blood from the indicator introduction or values related to the indicator introduction which can be transmitted or transferred by means of diffusion, electro-magnetic or thermal fields or by other means to the respective sensor.

[58] The pump 170 can be any of a variety of pumps types, including but not limited to a peristaltic, a roller, an impeller, or a centrifugal pump. The pump 170 induces a blood flow rate through the extracorporeal circuit 100. Depending on the specific configuration, the pump 170 can be directly controlled at the pump or can be controlled through the controller 180 to establish a given blood flow rate in the extracorporeal circuit 100. The pump 170 can be at any of a variety of locations in the extracorporeal circuit 100, and is not limited to the position shown in Fig. 1. In one configuration, the pump 170 is a commercially available pump and can be set or adjusted to provide any of a variety of flow rates wherein the flow rate can be read by a user and/or transmitted to and read by the controller 180.

[59] The normal or forward blood flow through the extracorporeal circuit 100 includes withdrawing blood through the arterial line 120 from the access device 200, passing the withdrawn blood through the extracorporeal circuit (to treat the blood in the dialyzer 130), and introducing the withdrawn (or treated) blood through the venous line 150 into the access device. The pump 170 can induce a blood flow through the extracorporeal circuit 100 from the access device 200 and back to the access device.

[60] The controller 180 is typically connectable to the blood treatment device 130, the pump 170 and the flow sensor 156 and the sensor 126, if employed. The controller 180 can be a stand-alone device such as a personal computer, a dedicated device or embedded in one of the components, such as the pump 170 or the blood treatment device 130. Although the controller 160 is shown as connected to the sensors 126 and 156, the pump 170 and the blood treatment device 120, it is understood the controller can be connected to only the sensors, the sensors and the pump, or any combination of the sensors, pump and blood treatment device 130.

[61] It has been discovered that the flow rate data from the venous line, including the flow rate in the venous line 150 is generally pulsatile with a frequency from the pump 170 as well as incorporating a component in response to physiology of the patient downstream of the measured flow rate data in the venous line. That is, there is a patient contribution to the flow rate data, and hence the flow rate, in the venous line 150, wherein at least a portion of the patient contribution to the obtained flow rate data corresponds to downstream physiological effects within the patient. Such portion of the patient contribution may include components from the pulse of the patient in the circulatory system, as well as a respiration component. As the flow through the extracorporeal circuit 100 is imparted by the pump 170 and the patient physiology is downstream of the venous line 150, it is a surprising discovery that there is a patient contribution to the flow rate in the venous line. As set forth below, it has been further discovered that the flow rate data from the arterial line 120 includes a patient contribution, wherein at least a portion of the patient contribution to the obtained flow rate data corresponds to physiological effects within the patient.

[62] The patient contribution to the flow rate data is generated by the patient physiology, and propagates through the access device 200, such as through needles in case of an AV shunt or from the central veins (or the heart) in case of the access device being a catheter interfacing with the circulatory system. It has been found that the patient contribution can be observed in the flow rate data, such as the blood flow rate, in the extracorporeal circuit 100, and particularly in the pulsatile flow of both the arterial line 120 and the venous line 150. It is noted that the patient contribution observed in the arterial line 120 is traversing predominantly from the arterial access of the extracorporeal circuit 100 and the flow rate data can be obtained in the arterial line. It is noted that any patient contribution propagating upstream from the venous line 150 to the arterial line 120 must pass through the pump 170, the blood treatment device 130, such as the dialyzer

and any bubble traps, each of which will substantially dampen the appearance of the patient contribution traversing from the venous access. That is, the patient contribution propagating upstream along the venous line 150 is substantially dampened as the contribution passes the pump 170, the blood treatment device 130 and any bubble traps and into the arterial line 120. Thus, of the flow rate data taken from the arterial line 120 the patient contribution is predominately that which has traversed downstream from the patient through the arterial line 120. Similarly, the patient contribution observed in the venous line 150 is predominantly the patient contribution that has propagated upstream along the venous line 150 from the access device 200. Any patient contribution propagating downstream along the arterial line 120 is substantially dampened as such contribution passes through the pump 170, the blood treatment device 130 and the any bubble traps and into the venous line 150. That is, in the flow rate data from the venous line 150, the patient contribution is dominated by the patient contribution that has propagated upstream along the venous line from the access device 200, (such as the needle or the venous catheter lumen) - as the pump 170, the blood treatment device 130 (the dialyzer), and any bubble traps substantially dampen any patient contribution propagating downstream from the arterial line 120 to the venous line 150. In the case of an arterial access disruption or disconnect, the pump 170 will suck air and hence blood flow through the extracorporeal circuit 100 will stop. However, in the case of a disruption or disconnect of the venous line 150, the flow in the arterial line 120 and hence the patient contribution in the arterial line may remain sufficiently unchanged to provide a reliable indicator of a disruption of the venous line.

[63] The controller 180 is programmed to identify the patient contribution to the flow rate data, such as in the blood flow rate in the venous line 150 and compare the patient contribution to the flow rate data across two different times, or identify a change in the patient contribution, such as a change of a predetermined level, or a lack of patient contribution in the flow rate data, or the measured flow rate.

[64] As seen in Fig. 2, the venous flow pulsates with frequency of approximately 68 beats/minute, which pulsation is related to a patient heart rate.

[65] As seen in Fig. 3, the flow rate in the arterial line 120 is pulsatile and dominated by the flow variations imparted by the pump 170, if the pump is of the peristaltic or roller-pump type.

The pulsation of approximately 48 beats/minute by the pump 170 can also be identified or known from the RPM of the pump or blood treatment device 130, if the pump is incorporated in to the blood treatment device.

[66] It has been found that a spectrum analysis of the flow rate data in the venous line 150, identifies various contributions, including a pump contribution on the pulsatile flow rate imparted by the pump 170 in the extracorporeal circuit 100, and the patient contribution. Generally, the flow rate data, such as the measured flow rate is analyzed to identify a magnitude of an input signal versus frequency within the full frequency range, so that the spectral components can be independently identified, and particularly the spectral components resulting from patient physiology, the patient contribution. The frequency domain provides for the identification of harmonic content in the flow rate data, such as the measured flow rate in the venous line 150, and thus provide for the identification of respective contributions to the pulsatile flow rate, including a patient contribution such as corresponding to a pulse or respiration rate of the patient.

[67] Generally, the present disclosure provides for acquiring sufficient flow rate data that allows for accurately quantifying or distinguishing the components of the flow rate data, and particularly in the frequency domain of the flow rate data. For example, the flow rate data as a function of time is obtained at sufficiently short time intervals to model each oscillation, variation, pulsation or frequency change and over a sufficient period such that multiple occurrences are included. The controller 180 then decomposes the flow rate data on the hypothesis that the acquired signal is composed of a sum of individual oscillatory components. Thus, the controller 180 decomposes functions depending time into functions depending on spatial or temporal frequency, whereby the patient contributions to the resolved frequencies can be identified.

[68] In one configuration, the spectrum analysis can be provided by Discrete Fourier Transform (DFT) and particularly the Fast Fourier Transform (FFT). The DFT interprets or transforms a time domain function into a series of sine-waves at various frequencies, the sum of which can reconstruct the signal. The so-called spectrum of frequency components is the frequency-domain depiction of the signal (such as the measured flow rate and the pulsatile

pattern of the flow waveform or flow rate data). The frequency analysis provides a different way of looking at the same flow rate data of the flow in the venous line 150. Instead of observing the flow rate data, or the flow rate in the time domain, the frequency analysis decomposes time data in its series of sine waves. The (FFT) is a well-known mathematical method for transforming a function in time into a function of frequency. A commercially available spectrum analyzer or a software application in the controller 180 converts the flow rate data, such as the measured magnitude pattern of an input signal into its frequency components within the full frequency range.

[69] Referring to Fig. 4, which is a FFT of the venous flow rate data of Fig. 2, a first harmonic of the pump frequency derived from the flow rate data in the venous line 150 is shown. Also shown in the Fig. 4, is a first harmonic of the heart rate of the patient connected to the extracorporeal circuit 100 as derived from the flow rate data in the venous line 150, thus showing the presence of the patient contribution can correspond to the pulse of the patient.

[70] Referring to Fig. 5, which is a FFT of the arterial flow rate data Fig. 3, a first and second harmonic of the pump 170 is shown. It is also contemplated that this harmonic also can be known or derived from the operating parameters of the pump 130, such as revolutions per minute of the pump. It is also noted, the heart rate harmonic is also observed in the arterial flow rate data. However, it is understood that in the case of flow disruption between the venous line 150 and the patient circulatory system, such as venous needle dislodgement, the heart rate harmonic in the arterial line 120 will still remain or be present, as the signal propagates from arterial access of the arterial line.

[71] Referring to Fig. 6, which combines the arterial and venous flow rate data, the spectrum analysis via FFT confirms, that the patient contribution, the heart rate, and the contribution from the pump 170 are observed by both flow sensors, that is the flow sensor 126 in the arterial line 120 and the flow sensor 156 in the venous line 150.

[72] Thus, the controller 180 is configured to apply the spectrum analysis to the flow rate data, such as a calculated or measured flow rate in the venous line 150, to identify at least one patient contribution to the flow rate data. By then monitoring the identified patient contribution,

the controller 180 can provide an alarm or pump control in response to a change in, such as a termination of, the patient contribution.

[73] While the Fourier Transform is set forth for the decomposition of the acquired flow rate data, it is understood that other ways of signal analysis can be used to extract information from the flow rate data about presence of the patient contribution to the flow rate data in the extracorporeal circuit, such as in the venous line 150 and particularly the patient contribution from the patient physiology for the monitoring of the presence of the patient contribution in the venous line.

[74] Referring to Fig. 7, the flow rate in the venous line 150 is shown, wherein the flow rate includes a pulsatile component. Fig. 8 is a graph of the flow rate in the arterial line 120 of the extracorporeal circuit 100 of Fig. 7. Fig. 9 is a spectrum analysis of the flow rate data, specifically the flow rate, of Fig. 7. As seen in Fig. 10, the harmonics from the pump 170 are pronounced and are the dominate harmonics. Referring to Fig. 9, while the harmonics from the pump 170 are the dominate harmonics, the harmonics from the patient physiological process, the patient contribution, are identifiable. That is, harmonics from downstream physiological processes are identified in the blood flow rate in the venous line 150. Thus, the controller 180 can monitor for an absence or change of a predetermined amount of the patient contribution to detect a disruption of the flow from the venous line 150 of the extracorporeal circuit 100 to the patient blood delivery site, such as the vascular device 200.

[75] Thus, the system can be configured to monitor the extracorporeal circuit 100 extending from the access device 200 through the extracorporeal blood treatment device 130, such as a dialyzer, and back to the access device, wherein the extracorporeal circuit includes the arterial line 120 extending from the access device to the blood treatment device, the venous line 150 extending from the blood treatment device to the vascular access, and the pump 170 connected to the extracorporeal circuit to pump blood from the access device, through the extracorporeal circuit from the arterial line, through the blood treatment device and through the venous line to the access device. The system includes the flow sensor 156 for obtaining flow rate data of a blood flow in the venous line 150; and the controller in communication with the flow sensor, wherein the controller 180 is configured to determine, based on the flow rate data, a flow rate in

the venous line; identify, in the determined flow rate, at least one patient contribution to the flow rate from a downstream patient physiological process, such as by spectrum analysis and particularly FFT; and detect, based at least partly on the identified patient contribution, a disruption of the extracorporeal blood path downstream of the pump 170. That is, the controller 180 can be configured to identify an absence of a previously identified patient contribution as seen in the spectrum analysis. This identified absence from the spectrum analysis can be used to identify a disruption of the flow from the extracorporeal circuit 100 to the access device 200 (or the circulatory system), wherein an alarm is provided and/or the pump 170 is stopped. As set forth above, it is understood the disruption can include venous needle dislodgement.

[76] In addition to the transforms set forth above that provide frequency components and hence comparison or monitoring of the frequency components, it is understood that as Fourier analysis requires a continuous waveform, it is contemplated that selected data points can be obtained wherein the controller 180 then applies a predictive model, such as but not limited to an AI algorithm, to the separate data points to generate for example, a predictive pattern of the waveform, wherein the disruption can be identified as soon as a change is seen in the time domain. Thus, the controller 180 can identify changes in the patient contribution in either the frequency domain and/or the time domain. Further, it is contemplated the controller 180 can also identify a change in a correlation between either obtained or predicted the flow rate data from either or both the arterial line and the venous line, such as the flow wave form pattern and the next obtained or predicted pattern, such as emerging by the next heartbeat.

[77] The controller 180 can be configured to improve the identification of the patient physiological parameter (or a plurality of patient physiological parameters) in the flow rate data from the blood delivery (venous) line 150, such as by the correlation of flow rate data between the blood delivery (venous) line and the blood withdrawal (arterial) line 120. For example, one flow sensor 156 is operably connected to the blood delivery (venous) line 150 to generate blood delivery line flow rate data and a second flow sensor 126 is operably coupled to the blood withdrawal (arterial) line 120 to generate blood withdrawal line flow rate data, wherein the controller is configured to identify at least one patient physiological parameter (patient contribution) or a change in the patient physiological parameter through a relationship of the flow rate data from the blood withdrawal line and the flow rate data from the blood delivery line.

In one configuration, the relationship is a correlation of the flow rate data from the blood withdrawal line and the flow rate data from the blood delivery line.

[78] It is further understood that the controller 180 may receive information from the blood treatment device 130 and or the pump 170, such as a blood flow or revolutions per minute setting, so as to discern between transform (Fourier) components in the obtained flow rate data, thereby distinguishing between flow rate data generated by the pump 170 and by the patient contribution to the flow rate data, such as by the heart rate of the patient.

[79] It is contemplated the controller 180 is connected to the flow sensor 156, wherein the flow sensor senses a flow through the venous line 150. The controller 180 is configured to identify a disruption in a blood flow path downstream of the flow sensor corresponding to a change in a patient contribution to the flow rate in the venous line 150. The change in a patient contribution to the flow rate data, or the flow rate, in the venous line 150 can be detected by a change in the patient contribution as indicated by the change in the detected harmonics from the spectrum analysis, as well as a temporary spike in the flow rate when the venous line is exposed to atmospheric pressure rather than the pressure in the access device 200, such as the venous access. It is contemplated that when the venous line 150 is exposed to atmospheric pressure, a related spike in the blood flow may be detected due to the decrease of resistance to blood flow in the venous line.

[80] The present system provides a method including the steps of identifying a disruption of the venous line 150 of the extracorporeal circuit 100 and the patient circulatory system, such as via the access device 200, wherein the disruption corresponds to a change in a patient contribution to the flow rate in the venous line and wherein the change in the patient contribution to the flow rate in the venous line corresponds to a change in an identified harmonic in the spectrum analysis, where the identified harmonic results from downstream physiology of the patient.

[81] The present system provides a further method including identifying at least one patient contribution, from a downstream patient physiological function, of the measured flow rate in the venous line 150 of an extracorporeal circuit 100; and monitoring the patient contribution to identify a disruption of vascular access between the extracorporeal circuit 100 and the circulatory

system. The monitoring can include an absence of presence of the harmonic as well as a rate of change in the identified harmonic or the value of the harmonic relative to a predetermined level or threshold.

[82] The methods of the present disclosure include measuring the flow rate in the venous line 150 and identifying a disruption of the connection of the venous line and the circulatory system of the patient corresponding to a change of a component of the flow rate, which component corresponds to a physiological parameter of the downstream circulatory system connected to the venous line. The change in the component can be detected by the corresponding change in the spectrum analysis of the measured flow rate in the venous line 150.

[83] Thus, the present disclosure provides for monitoring the extracorporeal blood treatment device that includes the extracorporeal circuit 100, wherein the extracorporeal circuit includes the arterial line 120 with the arterial patient connection and the venous line 150 with the venous patient connection, and the pump 170 for conveying blood in the extracorporeal circuit. The method includes measuring the flow rate in the venous line 150 of the extracorporeal circuit 100; identifying at least one patient contribution of the measured flow rate corresponding to a downstream physiological parameter of the patient; and determining the presence of a disruption in the flow between the extracorporeal circuit and the circulatory system in response to a change in the patient contribution to the measured flow rate. In identifying the patient contribution, the spectrum analysis identifies frequencies corresponding to the downstream physiology of the patient, and thus a given change in the identified frequency can trigger an alarm or change in status of the pump 170.

[84] The present disclosure sets forth systems and methods for determining when a disruption occurs in the flow from the extracorporeal circuit 100 to the patient circulatory system, such as when a needle or cannula has been removed from the patient, or when the connection of the blood treatment device 130 to the venous needle or to the venous catheter lumen is disrupted, such as disconnected. That is, the disruption of the flow from the extracorporeal circuit 100 to the patient circulatory system includes a disruption of the flow in the extracorporeal circuit downstream of the pump 170. For example, the disruption can be an interruption of the flow from the pump to the venous line 150, or from the blood treatment device 130 to the venous line,

as well as the between the venous line and the patient access, or the patient access 200 to the circulatory system.

[85] One primary use for the systems and methods is with blood treatments that remove blood from the patient, treat the blood and return the treated blood to the patient. As set forth above, typical blood treatments include hemodialysis (“HD”), hemofiltration (“HF”), hemodiafiltration (“HDF”) and continuous renal replacement treatment (“CRRT”) systems each remove blood from the patient, filter the blood, and return the blood to the patient. However, it is understood that besides these blood treatments, the access disconnection systems and methods discussed herein could be used in cardio pulmonary bypass surgeries in which blood is removed from the patient, oxygenated, and returned to the patient. Further, the disruption detection can be used with single needle systems, such as certain medical delivery systems in which a drug or medicament is infused from a source to the patient. Additionally, the disruption detection can be used in single or double needle aphaeresis or other blood separation and/or collection systems, such as for separating platelets, plasma, red cells or cell subpopulations.

[86] The present disclosure thus provides a method including (a) identifying a patient contribution, from a downstream patient physiological function in flow rate data from a blood delivery line of an extracorporeal circuit; and (b) monitoring the patient contribution to identify a disruption of a flow from the extracorporeal circuit to a patient circulatory system. The method can further comprise generating alert/alarm upon identifying the disruption of a vascular access.

[87] The present disclosure thus provides a method including (a) obtaining flow rate data of a flow in a blood delivery line of an extracorporeal circuit, the extracorporeal circuit having a pump imparting the flow in the blood delivery line; and (b) identifying a disruption of a connection of the extracorporeal circuit and a downstream patient circulatory system, the disruption corresponding to a change of a component of the flow rate data, wherein the component corresponds to a physiological parameter of the downstream patient circulatory system.

[88] The present disclosure further provides a method for monitoring an extracorporeal blood treatment apparatus including an extracorporeal circuit, the extracorporeal circuit having an arterial line with an arterial patient connection and a venous line with a venous patient

connection, and a pump for conveying blood in the extracorporeal circuit, the method including the steps of (a) sensing blood flow rate data in the venous line of the extracorporeal circuit; (b) identifying a patient contribution of the sensed blood flow rate data corresponding to a downstream physiological parameter of the patient; and (c) determining a disruption of a blood flow from the venous line in response to a change identified in the patient contribution to the sensed blood flow rate data. The method can further include generating a control signal to activate an alarm unit, stop the pump, or both, after the step of determining the disruption is present.

[89] This disclosure has been described in detail with particular reference to an embodiment, but it will be understood that variations and modifications can be effected within the spirit and scope of the disclosure. The presently disclosed embodiments are therefore considered in all respects to be illustrative and not restrictive. The scope of the invention is indicated by the appended claims, and all changes that come within the meaning and range of equivalents thereof are intended to be embraced therein.

CLAIMS

1. An apparatus for monitoring an extracorporeal circuit extending from a patient blood withdrawal site through an extracorporeal blood treatment device and back to a patient blood delivery site, wherein the extracorporeal circuit comprises a blood withdrawal line extending from the patient blood withdrawal site to the blood treatment device, a blood delivery line extending from the blood treatment device to the patient blood delivery site, and a pump operable to pump blood through the extracorporeal circuit from the blood withdrawal line, through the blood treatment device and through the blood delivery line to the patient blood delivery site, the apparatus comprising:
 - (a) a flow sensor configured to obtain flow rate data of a blood flow in at least one of the blood withdrawal line and the blood delivery line; and
 - (b) a controller in communication with the flow sensor, the controller configured to:
 - (i) identify, in the flow rate data, a patient contribution to the flow rate data from a patient physiological process; and
 - (ii) detect, based at least partly on the identified patient contribution, a disruption of the extracorporeal blood path.
2. The apparatus of Claim 1, wherein the identified patient contribution is a frequency of the flow rate data in a frequency domain of the flow rate data.
3. The apparatus of Claim 1, wherein the identified patient contribution is a patient generated component of a flow rate in the blood delivery line.
4. The apparatus of Claim 1, wherein the controller is configured to determine, based on the flow rate data, a flow rate in the blood delivery line.
5. The apparatus of Claim 1, wherein the disruption is a venous needle dislodgement.
6. The apparatus of Claim 1, wherein the blood treatment device is a dialyzer.
7. The apparatus of Claim 1, wherein the controller is configured to stop the pump in response to the detected disruption.
8. The apparatus of Claim 1, wherein the flow sensor obtains the flow rate data from the blood delivery line.

9. The apparatus of Claim 1, wherein the controller is configured to generate an alarm signal and or stop pump signal in response to detecting the disruption.

10. The apparatus of Claim 1, wherein the controller is configured to identify the patient contribution from a spectrum analysis of the flow rate data.

11. The apparatus of Claim 1, wherein the flow sensor is operably connected to the blood delivery line and further comprising a second flow sensor operably coupled to the blood withdrawal line to generate withdrawal line flow rate data, and wherein the controller is configured to identify the patient contribution based on the withdrawal line flow rate data and the flow rate data.

12. The apparatus of Claim 1, wherein the controller is configured to identify a contribution to the flow rate data corresponding to the pump.

13. A controller connected to a flow sensor providing flow rate data of a flow through a blood delivery line of an extracorporeal circuit, the controller configured to identify a disruption in a blood flow from the extracorporeal circuit to a patient circulatory system corresponding to a change in a patient contribution in the provided flow rate data.

14. The controller of Claim 13, wherein the controller is configured to identify the patient contribution from a spectrum analysis of the provided flow rate data of the flow the blood delivery line.

15. The controller of Claim 13, wherein the controller is configured to identify the patient contribution as a harmonic of the provided flow rate data.

16. The controller of Claim 13, wherein the controller is configured to identify patient contribution as a frequency of the flow rate data in a frequency domain of the flow rate data.

17. A method comprising:


(a) identifying a disruption of a connection of a blood delivery line of an extracorporeal circuit and a patient circulatory system, wherein the disruption corresponds to one of a change in and a disappearance of, a patient contribution to a flow rate data of a flow in the blood delivery line.

18. The method of Claim 17, wherein the patient contribution is a harmonic in a frequency domain function of the flow rate data.

19. The method of Claim 17, wherein the patient contribution corresponds to a physiological parameter of the circulatory system downstream of the blood delivery line.

20. The method of Claim 17, wherein the patient contribution is a frequency of the flow rate data in a frequency domain of the flow rate data.

Fig. 1






Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 9




Fig. 10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/038495

A. CLASSIFICATION OF SUBJECT MATTER A61M 1/36(2006.01)i; A61B 5/026(2006.01)i		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61M 1/36(2006.01); A61M 1/00(2006.01); A61M 1/16(2006.01); A61M 1/28(2006.01); A61M 37/00(2006.01)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Korean utility models and applications for utility models Japanese utility models and applications for utility models		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) eKOMPASS(KIPO internal) & Keywords: extracorporeal, blood, delivery, pump, flow, sensor, identify, physiological, contribution		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 10973973 B2 (FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH) 13 April 2021 (2021-04-13) columns 2, 3, 5-7 ; claims 1, 5; figure 1	1-20
Y	US 2019-0217002 A1 (KABUSHIKI KAISYA ADVANCE) 18 July 2019 (2019-07-18) paragraphs [210], [287]; claim 1	1-20
A	US 7004924 B1 (BRUGGER et al.) 28 February 2006 (2006-02-28) whole document	1-20
A	US 10744253 B2 (MEDTRONIC, INC.) 18 August 2020 (2020-08-18) whole document	1-20
A	US 2012-0059305 A1 (AKINGBA) 08 March 2012 (2012-03-08) whole document	1-20
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "D" document cited by the applicant in the international application "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 14 November 2022		Date of mailing of the international search report 14 November 2022
Name and mailing address of the ISA/KR Korean Intellectual Property Office 189 Cheongsa-ro, Seo-gu, Daejeon 35208, Republic of Korea Facsimile No. +82-42-481-8578		Authorized officer PARK, Hye Lyun Telephone No. +82-42-481-3463

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US2022/038495

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)	Publication date (day/month/year)
US	10973973	B2	13 April 2021	EP 2519282	B1 19 October 2016
				EP 3141272	A1 15 March 2017
				EP 3141272	B1 24 July 2019
				JP 2013-515523	A 09 May 2013
				JP 2016-027860	A 25 February 2016
				JP 5840622	B2 06 January 2016
				JP 6111299	B2 05 April 2017
				US 10022485	B2 17 July 2018
				US 2012-0330214	A1 27 December 2012
				US 2018-0318492	A1 08 November 2018
				WO 2011-079941	A1 07 July 2011
US	2019-0217002	A1	18 July 2019	AU 2017-323136	A1 11 April 2019
				BR 112019004444	A2 28 May 2019
				CA 3035955	A1 15 March 2018
				CL 2019000580	A1 29 November 2019
				CN 109803694	A 24 May 2019
				CN 109803694	B 21 September 2021
				EP 3511033	A1 17 July 2019
				JP 2018-043003	A 22 March 2018
				JP 6526759	B2 05 June 2019
				KR 10-2019-0050982	A 14 May 2019
				MX 2019002735	A 26 August 2019
				PH 12019500504	A1 27 May 2019
				WO 2018-047956	A1 15 March 2018
US	7004924	B1	28 February 2006	US 2001-0021817	A1 13 September 2001
				WO 02-070042	A1 12 September 2002
				WO 02-070042	B1 31 October 2002
US	10744253	B2	18 August 2020	CN 107729709	A 23 February 2018
				EP 3290069	A2 07 March 2018
				EP 3290069	A3 25 April 2018
				US 2018-0043078	A1 15 February 2018
US	2012-0059305	A1	08 March 2012	US 2009-0062669	A1 05 March 2009
				US 8057421	B2 15 November 2011
				US 8652084	B2 18 February 2014
				WO 2009-021241	A1 12 February 2009